Apellis Pharmaceuticals Stock Market Value
| APLS Stock | USD 22.05 0.26 1.17% |
| Symbol | Apellis |
Is there potential for Biotechnology market expansion? Will Apellis introduce new products? Factors like these will boost the valuation of Apellis Pharmaceuticals. If investors know Apellis will grow in the future, the company's valuation will be higher. Understanding fair value requires weighing current performance against future potential. All the valuation information about Apellis Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Apellis Pharmaceuticals is measured differently than its book value, which is the value of Apellis that is recorded on the company's balance sheet. Investors also form their own opinion of Apellis Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Apellis Pharmaceuticals' true underlying value. Analysts utilize numerous techniques to assess fundamental value, seeking to purchase shares when trading prices fall beneath estimated intrinsic worth. Because Apellis Pharmaceuticals' market value can be influenced by many factors that don't directly affect Apellis Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Understanding that Apellis Pharmaceuticals' value differs from its trading price is crucial, as each reflects different aspects of the company. Evaluating whether Apellis Pharmaceuticals represents a sound investment requires analyzing earnings trends, revenue growth, technical signals, industry dynamics, and expert forecasts. Meanwhile, Apellis Pharmaceuticals' quoted price indicates the marketplace figure where supply meets demand through bilateral consent.
Apellis Pharmaceuticals 'What if' Analysis
In the world of financial modeling, what-if analysis is part of sensitivity analysis performed to test how changes in assumptions impact individual outputs in a model. When applied to Apellis Pharmaceuticals' stock what-if analysis refers to the analyzing how the change in your past investing horizon will affect the profitability against the current market value of Apellis Pharmaceuticals.
| 11/14/2025 |
| 02/12/2026 |
If you would invest 0.00 in Apellis Pharmaceuticals on November 14, 2025 and sell it all today you would earn a total of 0.00 from holding Apellis Pharmaceuticals or generate 0.0% return on investment in Apellis Pharmaceuticals over 90 days. Apellis Pharmaceuticals is related to or competes with Catalyst Pharmaceuticals, Kiniksa Pharmaceuticals, Mineralys Therapeutics, Beam Therapeutics, Adaptive Biotechnologies, Scholar Rock, and Ideaya Biosciences. Apellis Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery, development, and ... More
Apellis Pharmaceuticals Upside/Downside Indicators
Understanding different market momentum indicators often help investors to time their next move. Potential upside and downside technical ratios enable traders to measure Apellis Pharmaceuticals' stock current market value against overall market sentiment and can be a good tool during both bulling and bearish trends. Here we outline some of the essential indicators to assess Apellis Pharmaceuticals upside and downside potential and time the market with a certain degree of confidence.
| Downside Deviation | 3.77 | |||
| Information Ratio | 0.0327 | |||
| Maximum Drawdown | 25.67 | |||
| Value At Risk | (3.83) | |||
| Potential Upside | 5.01 |
Apellis Pharmaceuticals Market Risk Indicators
Today, many novice investors tend to focus exclusively on investment returns with little concern for Apellis Pharmaceuticals' investment risk. Other traders do consider volatility but use just one or two very conventional indicators such as Apellis Pharmaceuticals' standard deviation. In reality, there are many statistical measures that can use Apellis Pharmaceuticals historical prices to predict the future Apellis Pharmaceuticals' volatility.| Risk Adjusted Performance | 0.0524 | |||
| Jensen Alpha | 0.1446 | |||
| Total Risk Alpha | (0.13) | |||
| Sortino Ratio | 0.0314 | |||
| Treynor Ratio | 0.3005 |
Apellis Pharmaceuticals February 12, 2026 Technical Indicators
| Cycle Indicators | ||
| Math Operators | ||
| Math Transform | ||
| Momentum Indicators | ||
| Overlap Studies | ||
| Pattern Recognition | ||
| Price Transform | ||
| Statistic Functions | ||
| Volatility Indicators | ||
| Volume Indicators |
| Risk Adjusted Performance | 0.0524 | |||
| Market Risk Adjusted Performance | 0.3105 | |||
| Mean Deviation | 2.53 | |||
| Semi Deviation | 3.68 | |||
| Downside Deviation | 3.77 | |||
| Coefficient Of Variation | 1817.4 | |||
| Standard Deviation | 3.62 | |||
| Variance | 13.1 | |||
| Information Ratio | 0.0327 | |||
| Jensen Alpha | 0.1446 | |||
| Total Risk Alpha | (0.13) | |||
| Sortino Ratio | 0.0314 | |||
| Treynor Ratio | 0.3005 | |||
| Maximum Drawdown | 25.67 | |||
| Value At Risk | (3.83) | |||
| Potential Upside | 5.01 | |||
| Downside Variance | 14.2 | |||
| Semi Variance | 13.52 | |||
| Expected Short fall | (2.77) | |||
| Skewness | (0.87) | |||
| Kurtosis | 5.06 |
Apellis Pharmaceuticals Backtested Returns
Apellis Pharmaceuticals appears to be not too volatile, given 3 months investment horizon. Apellis Pharmaceuticals secures Sharpe Ratio (or Efficiency) of 0.055, which signifies that the company had a 0.055 % return per unit of standard deviation over the last 3 months. We have found twenty-eight technical indicators for Apellis Pharmaceuticals, which you can use to evaluate the volatility of the firm. Please makes use of Apellis Pharmaceuticals' mean deviation of 2.53, and Risk Adjusted Performance of 0.0524 to double-check if our risk estimates are consistent with your expectations. On a scale of 0 to 100, Apellis Pharmaceuticals holds a performance score of 4. The firm shows a Beta (market volatility) of 0.63, which signifies possible diversification benefits within a given portfolio. As returns on the market increase, Apellis Pharmaceuticals' returns are expected to increase less than the market. However, during the bear market, the loss of holding Apellis Pharmaceuticals is expected to be smaller as well. Please check Apellis Pharmaceuticals' maximum drawdown, and the relationship between the information ratio and expected short fall , to make a quick decision on whether Apellis Pharmaceuticals' price patterns will revert.
Auto-correlation | -0.45 |
Modest reverse predictability
Apellis Pharmaceuticals has modest reverse predictability. Overlapping area represents the amount of predictability between Apellis Pharmaceuticals time series from 14th of November 2025 to 29th of December 2025 and 29th of December 2025 to 12th of February 2026. The more autocorrelation exist between current time interval and its lagged values, the more accurately you can make projection about the future pattern of Apellis Pharmaceuticals price movement. The serial correlation of -0.45 indicates that just about 45.0% of current Apellis Pharmaceuticals price fluctuation can be explain by its past prices.
| Correlation Coefficient | -0.45 | |
| Spearman Rank Test | -0.4 | |
| Residual Average | 0.0 | |
| Price Variance | 3.65 |
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for Apellis Stock Analysis
When running Apellis Pharmaceuticals' price analysis, check to measure Apellis Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Apellis Pharmaceuticals is operating at the current time. Most of Apellis Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Apellis Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Apellis Pharmaceuticals' price. Additionally, you may evaluate how the addition of Apellis Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.